Advertisement
BAX vs BDX
Which Stock Would AI Choose? Baxter International (BAX) vs. Becton Dickinson (BDX) Stock Comparison
Key Takeaways
- Both BAX and BDX are healthcare suppliers, but they occupy very different positions: Baxter is a mid-cap turnaround story, while Becton Dickinson is a large-cap diversified MedTech (medical technology) leader.
- Becton Dickinson (BDX) delivers consistently higher margins, broader scale, and steadier growth, while Baxter (BAX) is working through a post-divestiture restructuring, margin pressure, and a reduced dividend.
- Tickeron AI Verdict: BDX — Becton Dickinson's more consistent trend, stronger profitability, and diversified platform give it the relative edge over Baxter in the current environment.
- Baxter's recent results show improving revenue and raised guidance, but its turnaround remains vulnerable to a product-hold issue and balance-sheet constraints.
- For more detail, explore BAX Major News and BAX Today's Price Move, or BDX Major News and BDX Today's Price Move.
- To see how AI evaluates opportunities like these in real time, explore Trending AI Robots.
Introduction
Baxter International (BAX) and Becton Dickinson (BDX) both operate at the intersection of healthcare and medical supplies, yet they appeal to different kinds of investors. Baxter is a value-oriented turnaround candidate restructuring after selling its kidney care business, while Becton Dickinson is a diversified MedTech franchise realigning itself around higher-growth platforms after spinning off its life sciences segment. This stock comparison is relevant for traders and investors weighing a cyclical recovery story against a more established, cash-generative operator. Understanding their relative performance, market positioning, and risk profiles helps clarify which name may be better suited to the current market backdrop.
BAX Overview and Recent Performance
BAX, or Baxter International, provides injectable therapies, infusion pumps, surgical sealants and hemostats, patient monitoring, and hospital equipment acquired through its Hillrom purchase. In recent quarters the company has shown steady improvement under new leadership, with sales growth across its segments and rising free cash flow. Its most recent quarterly results beat consensus, and management raised full-year guidance, signaling early progress in a multi-year turnaround.
Still, Baxter's relative performance has been shaped by unresolved challenges. The company cut its dividend to a nominal level, reflecting a focus on deleveraging after divesting its Kidney Care business. An ongoing shipment and installation hold on its Novum IQ large-volume infusion pump, alongside manufacturing, tariff, and pricing pressures, has weighed on margins and sentiment. The stock trades at a modest market capitalization and a low earnings multiple, reflecting the market's cautious view of execution risk.
BDX Overview and Recent Performance
BDX, or Becton Dickinson, is one of the world's largest pure-play medical technology companies, spanning medical essentials, connected care, biopharma systems, and interventional products. After completing the separation of its Biosciences and Diagnostic Solutions business (combined with Waters Corporation), BD now operates as a focused MedTech company. Recent quarters showed broad-based growth, with more than 90% of the portfolio expanding and double-digit gains in platforms such as biologic drug delivery, advanced patient monitoring, and PureWick.
BD has raised its adjusted EPS (earnings per share) outlook, generated strong free cash flow, and returned capital through share repurchases and dividends. However, the company faces margin pressure from tariffs, difficult comparisons in its Alaris infusion business, and higher leverage following the separation. The stock is significantly larger than Baxter, with higher gross and operating margins, positioning it as a more established but slower-growing franchise.
Trending AI Robots
Tickeron operates hundreds of AI trading bots that actively trade thousands of different tickers, each with its own trading style, strategy, timeframe, and performance profile. Rather than presenting every bot, Tickeron curates a focused Trending AI Robots page featuring only those best suited to current market conditions. These bots apply quantitative, algorithmic analysis to identify setups across momentum, trend, and mean-reversion approaches, giving traders a data-driven way to monitor names like BAX and BDX. With bots spanning diverse statistics and performance ranges, the platform offers options for different risk tolerances. Explore the Trending AI Robots page to review the current top performers and find strategies aligned with your approach.
Head-to-Head Comparison
The contrast between these two names is largely one of scale and maturity. Becton Dickinson generates roughly five times Baxter's revenue, carries a market capitalization of around $50 billion versus Baxter's mid-teens billions, and sustains meaningfully higher operating margins. Baxter's growth is tied to a narrower, hospital-centric portfolio and a recovery narrative, while BD's diversified platforms span infusion, pharmacy automation, biopharma delivery, and interventional devices.
Growth drivers differ as well. Baxter is focused on operational stabilization, balance-sheet repair, and resolving its infusion pump hold. BD is investing in higher-growth categories, including GLP-1 (glucagon-like peptide-1) biologic drug delivery programs, patient monitoring, and pharmacy automation. On risk, Baxter faces greater single-stock execution and leverage sensitivity, whereas BD's risks center on tariff costs, the Alaris comparison, and post-spin leverage. Market sentiment reflects these gaps: BD's valuation and liquidity profile suggest greater confidence, while Baxter's discount implies the market still prices in meaningful turnaround uncertainty.
Tickeron AI Verdict
Based on observable factors such as trend consistency, stability, catalysts, and relative positioning, Tickeron's AI would currently favor BDX over BAX. Becton Dickinson's diversified revenue base, higher margins, stronger free cash flow, and established capital-return program indicate a more consistent and stable trend profile. Baxter's improving results and raised guidance are encouraging, but its turnaround remains dependent on resolving product-hold issues and sustaining margin recovery, introducing greater variability. While both names carry sector-level risks, the probabilistic balance of trend consistency and financial stability currently leans toward Becton Dickinson.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BAX is a StrongBuy and BDX is a Buy.
BAX in upward trend: 10-day moving average broke above 50-day moving average on October 22, 2026
The 10-day moving average for BAX crossed bullishly above the 50-day moving average on October 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 77%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 03, 2026. You may want to consider a long position or call options on BAX as a result. In 47 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 55%.
The Moving Average Convergence Divergence (MACD) for BAX just turned positive on November 04, 2026. Looking at past instances where BAX's MACD turned positive, the stock continued to rise in 21 of 46 cases over the following month. The odds of a continued upward trend are 46%.
BAX moved above its 50-day moving average on November 03, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +2.96% 3-day Advance, the price is estimated to grow further. Considering data from situations where BAX advanced for three days, in 167 of 286 cases, the price rose further within the following month. The odds of a continued upward trend are 58%.
BAX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 144 of 210 cases where BAX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 69%.
Bearish Trend Analysis
The 10-day RSI Indicator for BAX moved out of overbought territory on October 16, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 32 similar instances where the indicator moved out of overbought territory. In 23 of the 32 cases, the stock moved lower in the following days. This puts the odds of a move lower at 72%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BAX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 67%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. BAX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 68 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 92 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.148) is normal, around the industry mean (4.964). P/E Ratio (-12.459) is within average values for comparable stocks, (40.591). BAX's Projected Growth (PEG Ratio) (36.677) is very high in comparison to the industry average of (4.143). Dividend Yield (0.002) settles around the average of (0.005) among similar stocks. P/S Ratio (1.057) is also within normal values, averaging (56.876).
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BAX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
BDX's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for BDX turned positive on October 09, 2026. Looking at past instances where BDX's MACD turned positive, the stock continued to rise in 26 of 45 cases over the following month. The odds of a continued upward trend are 58%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 12, 2026. You may want to consider a long position or call options on BDX as a result. In 54 of 102 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 53%.
BDX moved above its 50-day moving average on October 08, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for BDX crossed bullishly above the 50-day moving average on October 14, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 56%.
Following a +7.76% 3-day Advance, the price is estimated to grow further. Considering data from situations where BDX advanced for three days, in 134 of 294 cases, the price rose further within the following month. The odds of a continued upward trend are 46%.
The Aroon Indicator entered an Uptrend today. In 114 of 218 cases where BDX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 52%.
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BDX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 42%.
BDX broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 3 (best 1 - 100 worst), indicating outstanding price growth. BDX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 5 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 59 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Seasonality Score of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.364) is normal, around the industry mean (4.964). P/E Ratio (63.819) is within average values for comparable stocks, (40.591). Projected Growth (PEG Ratio) (1.107) is also within normal values, averaging (4.143). BDX has a moderately high Dividend Yield (0.020) as compared to the industry average of (0.005). P/S Ratio (2.290) is also within normal values, averaging (56.876).
The Tickeron SMR rating for this company is 85 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
BAX | BDX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 20 | 38 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 92 Overvalued | 75 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 59 | |
SMR RATING 1..100 | 94 | 85 | |
PRICE GROWTH RATING 1..100 | 39 | 3 | |
P/E GROWTH RATING 1..100 | 68 | 5 | |
SEASONALITY SCORE 1..100 | 50 | 65 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BDX's Valuation (75) in the Medical Specialties industry is in the same range as BAX (92). This means that BDX’s stock grew similarly to BAX’s over the last 12 months.
BDX's Profit vs Risk Rating (59) in the Medical Specialties industry is somewhat better than the same rating for BAX (100). This means that BDX’s stock grew somewhat faster than BAX’s over the last 12 months.
BDX's SMR Rating (85) in the Medical Specialties industry is in the same range as BAX (94). This means that BDX’s stock grew similarly to BAX’s over the last 12 months.
BDX's Price Growth Rating (3) in the Medical Specialties industry is somewhat better than the same rating for BAX (39). This means that BDX’s stock grew somewhat faster than BAX’s over the last 12 months.
BDX's P/E Growth Rating (5) in the Medical Specialties industry is somewhat better than the same rating for BAX (68). This means that BDX’s stock grew somewhat faster than BAX’s over the last 12 months.
| BAX | BDX | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 72% | 1 day ago 63% |
| Stochastic ODDS (%) | 1 day ago 69% | 1 day ago 48% |
| Momentum ODDS (%) | 1 day ago 55% | 1 day ago 53% |
| MACD ODDS (%) | 1 day ago 46% | 1 day ago 58% |
| TrendWeek ODDS (%) | 1 day ago 60% | 1 day ago 50% |
| TrendMonth ODDS (%) | 1 day ago 64% | 1 day ago 52% |
| Advances ODDS (%) | 1 day ago 58% | 6 days ago 46% |
| Declines ODDS (%) | 12 days ago 67% | 15 days ago 42% |
| BollingerBands ODDS (%) | 1 day ago 60% | 1 day ago 51% |
| Aroon ODDS (%) | 1 day ago 69% | 1 day ago 52% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BAX’s FA Score shows that 0 FA rating(s) are green while BDX’s FA Score has 2 green FA rating(s).
- BAX’s FA Score: 0 green, 5 red.
- BDX’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BAX’s TA Score shows that 7 TA indicator(s) are bullish while BDX’s TA Score has 6 bullish TA indicator(s).
- BAX’s TA Score: 7 bullish, 3 bearish.
- BDX’s TA Score: 6 bullish, 4 bearish.
Price Growth
BAX (@Pharmaceuticals: Other) experienced а +9.04% price change this week, while BDX (@Pharmaceuticals: Other) price change was +8.38% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +5.53%. For the same industry, the average monthly price growth was +4.73%, and the average quarterly price growth was +18.71%.
Reported Earning Dates
BAX is expected to report earnings on Feb 18, 2027.
BDX is expected to report earnings on Feb 04, 2027.
Industries' Descriptions
@Pharmaceuticals: Other (+5.53% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
Advertisement
BAX and
Correlation & Price change
A.I.dvisor indicates that over the last year, BAX has been loosely correlated with ICUI. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if BAX jumps, then ICUI could also see price increases.
| Ticker / NAME | Correlation To BAX | 1D Price Change % | ||
|---|---|---|---|---|
| BAX | 100% | +2.40% | ||
| ICUI - BAX | 56% Loosely correlated | +3.92% | ||
| LUNG - BAX | 53% Loosely correlated | +9.38% | ||
| STE - BAX | 51% Loosely correlated | +1.84% | ||
| SYK - BAX | 51% Loosely correlated | -0.04% | ||
| BDX - BAX | 49% Loosely correlated | +1.59% | ||
More | ||||
BDX and
Correlation & Price change
A.I.dvisor indicates that over the last year, BDX has been loosely correlated with COO. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if BDX jumps, then COO could also see price increases.